How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries

Sabine Vogler, Valérie Paris, Alessandra Ferrario, Veronika J. Wirtz, Kees de Joncheere, Peter Schneider, Hanne Bak Pedersen, Guillaume Dedet, Zaheer Ud Din Babar

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the hospital and offpatent outpatient sectors has been proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.

LanguageEnglish
Pages307-321
Number of pages15
JournalApplied Health Economics and Health Policy
Volume15
Issue number3
Early online date6 Jan 2017
DOIs
Publication statusPublished - Jun 2017
Externally publishedYes

Fingerprint

Costs and Cost Analysis
Medicine
Biosimilar Pharmaceuticals
Administrative Personnel
Benchmarking
Biomedical Technology Assessment
Aptitude
Confidentiality
Disclosure
Uncertainty
European countries
Pricing
Reimbursement
Lessons learned
Decision Making
Outpatients
Pharmaceutical Preparations
Transparency
Politicians
Therapeutics

Cite this

Vogler, Sabine ; Paris, Valérie ; Ferrario, Alessandra ; Wirtz, Veronika J. ; de Joncheere, Kees ; Schneider, Peter ; Pedersen, Hanne Bak ; Dedet, Guillaume ; Babar, Zaheer Ud Din. / How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. In: Applied Health Economics and Health Policy. 2017 ; Vol. 15, No. 3. pp. 307-321.
@article{201de6223ab34a73802e0f4262df8576,
title = "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries",
abstract = "This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the hospital and offpatent outpatient sectors has been proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.",
author = "Sabine Vogler and Val{\'e}rie Paris and Alessandra Ferrario and Wirtz, {Veronika J.} and {de Joncheere}, Kees and Peter Schneider and Pedersen, {Hanne Bak} and Guillaume Dedet and Babar, {Zaheer Ud Din}",
note = "No full text on ePrints.",
year = "2017",
month = "6",
doi = "10.1007/s40258-016-0300-z",
language = "English",
volume = "15",
pages = "307--321",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
publisher = "Adis International Ltd",
number = "3",

}

How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. / Vogler, Sabine; Paris, Valérie; Ferrario, Alessandra; Wirtz, Veronika J.; de Joncheere, Kees; Schneider, Peter; Pedersen, Hanne Bak; Dedet, Guillaume; Babar, Zaheer Ud Din.

In: Applied Health Economics and Health Policy, Vol. 15, No. 3, 06.2017, p. 307-321.

Research output: Contribution to journalArticle

TY - JOUR

T1 - How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries

AU - Vogler, Sabine

AU - Paris, Valérie

AU - Ferrario, Alessandra

AU - Wirtz, Veronika J.

AU - de Joncheere, Kees

AU - Schneider, Peter

AU - Pedersen, Hanne Bak

AU - Dedet, Guillaume

AU - Babar, Zaheer Ud Din

N1 - No full text on ePrints.

PY - 2017/6

Y1 - 2017/6

N2 - This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the hospital and offpatent outpatient sectors has been proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.

AB - This article discusses pharmaceutical pricing and reimbursement policies in European countries with regard to their ability to ensure affordable access to medicines. A frequently applied pricing policy is external price referencing. While it provides some benchmark for policy-makers and has been shown to be able to generate savings, it may also contribute to delay in product launch in countries where medicine prices are low. Value-based pricing has been proposed as a policy that promotes access while rewarding useful innovation; however, implementing it has proven quite challenging. For high-priced medicines, managed-entry agreements are increasingly used. These agreements allow policy-makers to manage uncertainty and obtain lower prices. They can also facilitate earlier market access in case of limited evidence about added therapeutic value of the medicine. However, these agreements raise transparency concerns due to the confidentiality clause. Tendering as used in the hospital and offpatent outpatient sectors has been proven to reduce medicine prices but it requires a robust framework and appropriate design with clear strategic goals in order to prevent shortages. These pricing and reimbursement policies are supplemented by the widespread use of Health Technology Assessment to inform decision-making, and by strategies to improve the uptake of generics, and also biosimilars. While European countries have been implementing a set of policy options, there is a lack of thorough impact assessments of several pricing and reimbursement policies on affordable access. Increased cooperation between authorities, experience sharing and improving transparency on price information, including the disclosure of confidential discounts, are opportunities to address current challenges.

UR - http://www.scopus.com/inward/record.url?scp=85008481918&partnerID=8YFLogxK

U2 - 10.1007/s40258-016-0300-z

DO - 10.1007/s40258-016-0300-z

M3 - Article

VL - 15

SP - 307

EP - 321

JO - Applied Health Economics and Health Policy

T2 - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 3

ER -